New drug targets Hard-to-Treat cancers by breaking down mutant protein
NCT ID NCT07023731
First seen Feb 20, 2026 · Last updated May 22, 2026 · Updated 13 times
Summary
This study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the faulty protein that helps tumors grow. The study has two parts: first, finding safe doses in small groups, then testing the best doses in people with pancreatic cancer. About 159 participants will receive the drug through an IV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trial Site
RECRUITINGPhoenix, Arizona, 85004, United States
-
Clinical Trial Site
RECRUITINGPhoenix, Arizona, 85054, United States
-
Clinical Trial Site
RECRUITINGNew Haven, Connecticut, 06510, United States
-
Clinical Trial Site
RECRUITINGTampa, Florida, 33612, United States
-
Clinical Trial Site
NOT_YET_RECRUITINGIndianapolis, Indiana, 46250, United States
-
Clinical Trial Site
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
Clinical Trial Site
RECRUITINGNew York, New York, 10032, United States
-
Clinical Trial Site
RECRUITINGNew York, New York, 10065, United States
-
Clinical Trial Site
RECRUITINGHuntersville, North Carolina, 28078, United States
-
Clinical Trial Site
RECRUITINGCleveland, Ohio, 44106, United States
-
Clinical Trial Site
RECRUITINGHouston, Texas, 77030-7009, United States
-
Clinical Trial Site
RECRUITINGSan Antonio, Texas, 78229, United States
-
Clinical Trial Site
RECRUITINGSalt Lake City, Utah, 84112, United States
-
Clinical Trial Site
RECRUITINGFairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.